Screener
Recursion Pharmaceuticals, Inc. RXRX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Net cash provided by (used in) financing activities | (4,737) | 138,186 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (3,019) | 14,088 |
| Net change in cash, cash equivalents and restricted cash | (197,101) | (69,179) |
| Cash, cash equivalents and restricted cash, beginning of period | 753,921 | 603,024 |
| Cash, cash equivalents and restricted cash, end of period | $556,820 | $533,845 |
| Supplemental schedule of non-cash investing and financing activities | ||
| Accrued property and equipment | 300 | 263 |
| Purchase of an equity investment | — | 4,438 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s cash & equivalents?
- Recursion Pharmaceuticals, Inc. (RXRX) reported cash & equivalents of $556.82M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s cash & equivalents changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s cash & equivalents increased by 4.3% year-over-year, from $533.85M to $556.82M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s cash & equivalents has grown at a 23.1% compound annual growth rate (CAGR), from $267.17M to $753.92M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Recursion Pharmaceuticals, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude